Texas Children's Cancer and Hematology Center A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations (SELVA)

This Phase 3 study evaluates the QTORIN 3.9% rapamycin gel topical treatment in individuals aged 3 years and older with microcystic lymphatic malformations.

Description

Microcystic lymphatic malformations are clusters of small, fluid-filled sacs caused by abnormal development of the lymphatic system. This study investigates QTORIN 3.9% rapamycin anhydrous gel, a topical treatment designed to reduce the size and symptoms of these malformations. Rapamycin works by targeting pathways involved in cell growth and inflammation. This trial is important because it offers a non-invasive treatment option for a condition that often requires surgery. The study also includes biomarker analysis to better understand treatment response.

Eligibility

• Age 3 years and older
• Diagnosis of superficial/cutaneous microcystic lymphatic malformations
• Willingness to comply with study procedures

Detailed inclusion and exclusion criteria are listed at clinicaltrials.gov